– UK, Sedgefield – Kromek PLC (LON: KMK), a worldwide supplier of detection technology focusing on the medical, security screening and nuclear markets, today announced the appointment of COO Berry Beumer to its Board as an Executive Director effective immediately.
Furthermore, Non-executive Director Rakesh Sharma OBE will replace Sir Peter Williams CBE as Non-Executive Chairman, following his retirement on 1 January 2021.
Rakesh Sharma OBE, Chairman Designate said: “It is a great honour to succeed Sir Peter as Chairman. I thank him for his valuable contribution which has enabled Kromek to truly transform during his tenure, and we wish him all the best in his retirement. I am also pleased to welcome Berry to the Board. He has played a fundamental role in our growth as part of the executive team and we look forward to further benefitting from his expertise in his new role. Kromek is an ambitious company with advanced technology, extensive IP and a foothold in some of the most important markets today. We are excited about the future and delivering on our plans to secure sustainable growth and shareholder value.”
Sir Peter Williams added: “It has been a pleasure to be a part of Kromek’s journey as it has matured and scaled up over recent years into a truly international business with diversified revenue streams. As I retire, I leave the role of Chairman in the very capable hands of Rakesh who brings tremendous experience in overseeing the growth of international hi-tech engineering and manufacturing businesses. I also congratulate Berry Beumer on joining the Board and, following Paul Farquhar’s recent appointment, I leave Kromek with a refreshed and powerful team at the helm under Arnab Basu’s leadership. I will be following the business closely and look forward to watching its continued progress.”
About Berry Beumer
Berry Beumer is a technology business executive with extensive experience of delivering revenue growth in the analytical instrument, high-frequency communications equipment and optoelectronic and semiconductor materials industries. Since joining Kromek as COO in 2015, based in the Group’s Pennsylvania facility, he has played an instrumental role in the growth of the business through the expansion of Kromek’s US customer base and operations in both medical imaging and nuclear detection. Before Kromek, he held several senior roles at businesses in Europe and the US, including 14 years as VP, Sales and Marketing at XOS, Inc., part off Danaher Inc., a leading manufacturer of application-specific x-ray analysers, where he was responsible for driving the strategic direction of their x-ray elemental technology business.
About Kromek Group plc
Kromek Group plc is a technology group and a leading developer of high-performance radiation detection products based on cadmium zinc telluride and other advanced technologies. Using its core technology platforms, Kromek designs, develops and produces x-ray and gamma-ray imaging and radiation detection products for the medical, security screening and nuclear markets.
The Group’s products provide high-resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.
The Group’s business model provides a vertically integrated technology offering to customers, from radiation detector materials to finished products or detectors, including software, electronics and application-specific integrated circuits.
The Group has operations in the UK and US (California and Pennsylvania) and is selling internationally through a combination of distributors and direct OEM sales.
Currently, the Group has over one hundred full-time employees across its global operations.
For more information: https://www.kromek.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
